MD Anderson, Artios Pharma and ShangPharma Announce In-licensing Agreement for DNA Damage Response Inhibitor
November 06, 2019
November 06, 2019
HOUSTON, Texas, Nov. 6 -- The University of Texas's MD Anderson Cancer Center issued the following news release:
The University of Texas MD Anderson Cancer Center, Artios Pharma Limited and ShangPharma Innovation today announce the in-licensing by Artios of a small-molecule ATR inhibitor program, developed jointly by MD Anderson and ShangPharma.
Under the agreement, Artios has exclusive rights to research, develop, manufacture and commercialize products globally. The le . . .
The University of Texas MD Anderson Cancer Center, Artios Pharma Limited and ShangPharma Innovation today announce the in-licensing by Artios of a small-molecule ATR inhibitor program, developed jointly by MD Anderson and ShangPharma.
Under the agreement, Artios has exclusive rights to research, develop, manufacture and commercialize products globally. The le . . .